Anti-IL-6Rα antibody tocilizumab was the first antagonist of the IL-6-signaling pathway to receive regulatory approval and is currently used for treating rheumatoid arthritis (14, –, 16). This evidence concerns the gene IL6 and rheumatoid arthritis.